The FDA has approved a polypill as an initial treatment for hypertension in adults for the first time.
Here’s what to know:
1. Widaplik — manufactured by George Medicines — is a polypill that contains telmisartan, amlodipine and indapamide.
2. Historically, monotherapies have been the initial treatment for hypertension. This is the first triple-combination medication to be approved for patients who are likely to need multiple drugs to achieve their blood pressure goals, according to a June 9 company release.
3. In trials, the polypill reduced systolic blood pressure by around 7 to 8 mm Hg versus placebo in people with mild-to-moderate hypertension. It also showed small but significant blood pressure reductions compared to other dual drug combinations.
4. Widaplik is expected to be available in fourth-quarter 2025.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.